PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3025% above fair value
$58.33−1.90 (-3.16%)
Close on Nov 19, 2026Market cap $4.87BP/E –Yield –
PTC Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
PTC Therapeutics's gross profit for the twelve months ending Dec 31, 2019 was $294.85M, up 17.0% year over year. For fiscal 2019 it was $294.85M, up 17.0% from the year before. The highest annual figure on record is $294.85M in fiscal 2019.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $294.85M | +17.0% |
| FY2018 | Dec 31, 2018 | $252.06M | +32.8% |
| FY2017 | Dec 31, 2017 | $189.82M | +129.5% |
| FY2016 | Dec 31, 2016 | $82.71M | +124.9% |
| FY2015 | Dec 31, 2015 | $36.77M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2019 | Dec 31, 2019 | $92.92M | +13.2% |
| Q3 FY2019 | Sep 30, 2019 | $68.41M | +36.0% |
| Q2 FY2019 | Jun 30, 2019 | $82.31M | +24.4% |
| Q1 FY2019 | Mar 31, 2019 | $51.21M | -3.4% |
| Q4 FY2018 | Dec 31, 2018 | $82.07M | +47.8% |
| Q3 FY2018 | Sep 30, 2018 | $50.30M | +25.1% |
| Q2 FY2018 | Jun 30, 2018 | $66.17M | +40.4% |
| Q1 FY2018 | Mar 31, 2018 | $53.02M | +100.8% |
| Q4 FY2017 | Dec 31, 2017 | $55.52M | +121.0% |
| Q3 FY2017 | Sep 30, 2017 | $40.20M | – |
| Q2 FY2017 | Jun 30, 2017 | $47.13M | – |
| Q1 FY2017 | Mar 31, 2017 | $26.40M | – |
| Q4 FY2016 | Dec 31, 2016 | $25.12M | – |
See a number that looks wrong?